CEO Executive AssistantPhase 3 clinical trials represent the most capital-intensive, time-sensitive, and organizationally demanding period in the biotech development lifecycle. Hundreds of sites must be activated globally. Thousands of patients must be recruited, enrolled, and followed. Regulatory relationships must be maintained and strengthened. Investors must be managed through an extended period of uncertainty. And simultaneously, the organization must begin preparing for the commercial future that a Phase 3 success will require.
For biotech CEOs, Phase 3 creates the most intense delegation demand in the company’s history to that point. The operational scope is too large for any individual to manage directly, and the strategic leadership required for investor relations, partnership development, and commercial readiness cannot be sacrificed to clinical operations management.
This guide describes specifically what biotech CEOs should delegate during Phase 3 and how to build the organizational systems that make effective delegation possible.
The Phase 3 Organizational Challenge
Phase 3 trials are fundamentally different from earlier development stages in ways that affect how delegation must be designed.
Scale. A Phase 3 trial may involve 300 to 1,000 or more clinical sites globally, thousands of patients, and hundreds of staff and CRO personnel. This scale requires industrial-grade project management, not the hands-on management that a smaller Phase 1 or 2 program might accommodate.
Regulatory intensity. During Phase 3, regulatory relationships are at their most active: FDA discussions about the trial design, protocol amendments, interim analysis decisions, safety monitoring, and pre-submission meetings all require sustained regulatory attention.
Timeline sensitivity. Phase 3 timelines directly affect investor confidence, partnership economics, and competitive positioning. Delays in enrollment or data generation create organizational pressure that can drive poor decisions if the CEO is managing timeline concerns operationally rather than strategically.
Commercial preparation parallel. For a company planning to launch commercially upon Phase 3 success, the 24 months of Phase 3 execution is the same window during which commercial organization building must begin. Managing both simultaneously requires disciplined delegation.
Investor relations intensity. Phase 3 is the period of maximum investor engagement: quarterly updates on enrollment progress, interim safety and efficacy signals, and ultimately the Phase 3 data readout are all high-stakes investor communications moments.
What Biotech CEOs Should Delegate During Phase 3
The following functions should be fully delegated to capable functional leaders during Phase 3, with the CEO maintaining oversight through reporting and governance rather than operational involvement.
Clinical Operations Management
A head of clinical operations or chief medical officer should own all clinical trial operations: site identification and selection, site initiation and activation, investigator training, patient recruitment strategy, clinical monitoring, data management, and trial execution overall.
A trial operations team, including clinical trial managers, clinical research associates, and data managers, executes the operational work under clinical operations leadership. The CEO receives regular clinical operations updates but is not managing site activation rates, monitoring visit schedules, or data query resolution.
CRO Management
Most biotech companies use CROs for Phase 3 execution, and managing CRO performance is a significant operational function. A clinical operations director or CRO alliance manager should own the CRO relationship: managing the CRO contract, monitoring CRO performance against milestones, resolving CRO performance issues, and coordinating between the CRO and internal teams.
The CEO engages with the CRO relationship at the strategic level: approving major CRO contracts, engaging with CRO senior leadership when significant performance issues arise, and making decisions when CRO performance requires strategic organizational response.
Regulatory Affairs Management
A chief regulatory officer or VP of regulatory affairs should own regulatory affairs during Phase 3: managing FDA interactions at the program level, overseeing the design of the regulatory submission strategy, managing the preparation of annual reports and protocol amendments, and leading pre-submission meeting preparation.
The CEO engages with regulatory affairs at the strategic level: participating in pre-NDA or pre-BLA meetings with FDA when CEO-level presence is appropriate, making decisions when regulatory strategy requires CEO authority, and engaging with regulatory leadership in high-stakes conversations.
For a broader framework on pharmaceutical CEO delegation across the development lifecycle, see our resource on pharma clinical ops.
Data Monitoring and Safety Surveillance
A drug safety or pharmacovigilance team should own ongoing safety surveillance: managing the safety database, reviewing adverse event reports, preparing safety reports for regulators and the data monitoring committee, and alerting the CMO and CEO when safety signals require strategic attention.
The independent data monitoring committee, which oversees interim safety and efficacy data, provides external governance of the trial’s scientific conduct. The CEO is informed of IDMC recommendations when they require organizational decisions.
Clinical Supply Chain
A clinical supply chain director should own the management of investigational product supply: clinical supply manufacturing oversight, distribution to clinical sites, supply forecasting, and resupply logistics. Supply disruptions during Phase 3 can derail enrollment and create regulatory concerns, making competent supply chain management a critical organizational function.
Finance and Budget Management
The CFO and finance team should own the Phase 3 budget: managing trial expenditures against budget, forecasting Phase 3 costs, managing CRO and site payment schedules, and ensuring that the company has adequate capital to complete the trial. The CEO engages with financial management at the level of major budget decisions and capital raising.
Medical Affairs Pre-Launch Preparation
As Phase 3 progresses, medical affairs activities that prepare for commercial launch must begin: MSL hiring and training, KOL scientific exchange programs, disease awareness education, and preparation for the Phase 3 data publication and presentation. A CMO or head of medical affairs should own this pre-launch medical affairs buildout.
What the CEO Manages During Phase 3
With the operational functions delegated, the CEO’s Phase 3 priorities become clear.
Investor Relations. The CEO is the primary investor voice during Phase 3. Quarterly enrollment updates, data readout preparation, and investor engagement at biotech conferences are CEO-level activities. An IR director prepares materials; the CEO presents and engages.
Partnership Development. Phase 3 is the period when larger pharmaceutical companies most actively evaluate licensing or co-development partnerships. The CEO leads partnership discussions, engages with potential partners’ senior leadership, and makes strategic decisions about deal structure and terms.
Commercial Readiness Oversight. As Phase 3 progresses, the CEO oversees the commercial readiness investments being made in parallel: CCO hiring, market access strategy development, and commercial infrastructure planning. These strategic decisions about the organization’s commercial future require CEO engagement.
Board Management. The board of directors has heightened engagement during Phase 3, as the company’s most significant financial investment and value creation milestone approaches. The CEO manages the board relationship, prepares for board meetings, and engages board members in Phase 3 strategy.
Senior Team Development. Phase 3 is an opportunity to develop the leadership team’s capacity through appropriate stretch assignments and coaching. The CEO invests in direct report development, preparing the team for the commercial-stage responsibilities that will follow a successful Phase 3 outcome.
Preparing for the Phase 3 Data Readout
The Phase 3 data readout is one of the highest-stakes moments in the biotech lifecycle. Preparing for this event requires both operational planning and strategic preparation.
A data readout preparation team, including the CMO, regulatory affairs, communications, and investor relations, should begin planning for the data readout 12 to 18 months before the anticipated completion of the trial. This includes: publication strategy planning, regulatory submission timeline finalization, investor communications scenario planning for both positive and negative outcomes, and commercial readiness milestone confirmation.
The CEO engages with data readout preparation at the strategic level: approving the overall communication strategy, preparing for investor communications in multiple outcome scenarios, and engaging with board members and major investors on preparation.
Managing Phase 3 Setbacks
Phase 3 trials encounter setbacks: enrollment delays, protocol amendments, safety signals, and ultimately the possibility of trial failure. The CEO’s role in managing setbacks is to maintain organizational stability, communicate transparently with investors, and make strategic decisions about how to respond.
When a setback occurs, the clinical operations and regulatory teams should manage the operational response. The CEO engages at the strategic level: making decisions about whether to amend the protocol, how to communicate with investors, whether to seek additional capital, and how to adjust organizational plans based on the new information.
According to Harvard Business Review, biotech CEOs who build robust clinical operations delegation and maintain their investor and partnership focus during Phase 3 achieve significantly better organizational outcomes, measured by trial completion rates, investor confidence, and partnership success, than those who become operationally enmeshed in trial management.
Building Phase 3 Delegation Readiness Before the Trial Begins
The time to build the delegation infrastructure for Phase 3 is before the trial begins, not after enrollment has started. By the time Phase 3 is underway, the organization should have:
A complete clinical operations team or CRO partnership with proven capabilities. A chief regulatory officer or experienced VP of regulatory affairs. A CFO who can manage the financial complexity of the Phase 3 budget. A communications and investor relations function that can manage Phase 3 investor communications. And a CEO who has consciously transferred Phase 2 operational management responsibilities to the clinical team, freeing their own capacity for the Phase 3 strategic leadership demands.
For guidance on structuring the full pipeline management delegation model, see our resource on pharma drug pipeline.
The biotech CEO who enters Phase 3 with a capable, delegated clinical operations function, their own time protected for strategic leadership, and clear organizational accountability for every dimension of the trial, is positioned to lead the organization through the most consequential period of its development to a successful outcome. That is what patients, investors, and the organization deserve.
Related Reading
For further context, explore What Biotech CEOs Should Delegate to Leadership Team and Automotive CEO Delegation for Aftermarket and Parts.